Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy
Zevra seeks to expand KP1077 clinical program to address multiple rare sleep disorders CELEBRATION, Fla., April 04, 2023 (GLOBE NEWSWIRE)...
Zevra seeks to expand KP1077 clinical program to address multiple rare sleep disorders CELEBRATION, Fla., April 04, 2023 (GLOBE NEWSWIRE)...
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months Aggregated Remission...
Opportunity to Accelerate Long-Term Organic Growth and Expand Patient AccessCINCINNATI, April 04, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp....
MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing Anika...
BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...
DURHAM, N.C., April 03, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life...
Celularity’s Pre-Request for Designation (Pre-RFD) is based on data demonstrating 100 percent biochemical characterization of the product Celularity intends to...
DELRAY BEACH, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS), Your Trusted Pet Health Expert™...
Turning the Page; A Promising FutureLOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Accelerated Pre-Investigational New Drug...
PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- The Annual Miles for Myeloma Hybrid 5K Run/Walk will once again “Redefine Being...
readabl.ai is a best-in-class AI and language processing model that help customers achieve maximum performance efficiency in workflow automationPLEASANTON, Calif.,...
– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™...
MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on...
Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count...
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the...
Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics ANAHEIM, CA, April 03, 2023...
Devin K. Schaffer, J.D., M.B.A, General Counsel, GeneDx GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic...